Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis

BACKGROUND There are few studies evaluating long-term glycemic control using a dipeptidyl peptidase-4 inhibitor in type 2 diabetes patients with end-stage renal disease (ESRD). The aim of this study was to evaluate the safety and efficacy of vildagliptin therapy over 2 years in type 2 diabetes with ESRD. METHODS Patients with ESRD resulting from type 2… CONTINUE READING